Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRM: Ferumoxytol vs FCM Safety Study in IDA
NCT02694978Phase 3Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Feb 2016
- Primary completion
- Jan 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of ferumoxytol in iron deficiency anemia (IDA) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Participants With Treatment-Emergent Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Or Moderate To Severe Hypotension. Started Feb 2016; status: completed.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02694978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694978.